Posted by: fuadelhibri on: December 15, 2010
ROCKVILLE, Md., Dec 06, 2010 (BUSINESS WIRE) – Emergent BioSolutions Inc. (NYSE: EBS) today announced the presentation of positive data from a Phase I dose escalation study of TRU-016 (Protocol 16007) at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida. In an oral presentation given yesterday, results from the [...]
